EndPoints Webinar 2022: November 16:
Why Oncology Needs More Than MRD


Stephane Mouradian

Stephane Mouradian, PhD
Senior Vice President, Business Development and Marketing
Personalis, Inc.

November 16, 2022 | 12:00 PM – 1:00 PM EST

Why Oncology Needs More Than MRD

In parallel with the evolution of cancer therapies over time, the field of molecular diagnostics continues to mature, bringing innovative solutions to precision medicine. The value of using molecular residual disease (MRD) to monitor a patient’s journey post-diagnosis has demonstrated value in oncology, but is this tool sufficient for clinicians to make informed treatment decisions throughout the patient’s journey? By combining multiple analyses in a platform-based approach, Personalis is developing a holistic solution to managing a patient’s care including therapy selection, treatment and recurrence monitoring, all from a single specimen collected at clinical diagnosis.

In this webinar, Stephane will present:

  • Example clinical use cases of a tumor-normal ctDNA assay
  • Technical validation data on a variety of cancer specimens
  • A future vision for comprehensive diagnostics in precision medicine